Amgen’s Rebate Bundling Makes It ‘Economically Unfeasible’ For Regeneron To Sell Praluent

Regeneron antitrust suit alleges Amgen’s bundling of Repatha rebates with Otezla and Enbrel has restricted Praluent’s market access and ability to compete with Repatha.

Rebate
Regeneron claims Amgen's rebate bundling is restricting access to Praluent • Source: Shutterstock

After winning a seven-year patent battle, Regeneron Pharmaceuticals, Inc. is once again in litigation with Amgen, Inc. over the PCSK9 inhibitor market. This time around, Regeneron claims Amgen is engaging in an anticompetitive rebate “bundling scheme” to keep its cholesterol-lowering drug Praluent (alirocumab) off third-party payor formularies.

In a 27 May complaint, Regeneron contends that Amgen is bundling sales of its competing PCSK9 inhibitor Repatha (evolocumab)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet